{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:28:27Z","timestamp":1787020107438,"version":"build-2736575974"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ursodeoxycholic acid is the preferred first-line therapy for primary biliary cholangitis. Alternative therapies, such as obeticholic acid, are recommended for patients who cannot tolerate ursodeoxycholic acid or who have an inadequate response to ursodeoxycholic acid monotherapy. Prior investigations have suggested that as many as 30% of patients with primary biliary cholangitis may have never received treatment with ursodeoxycholic acid. No prior investigations have examined usage rates of obeticholic acid in the treatment of primary biliary cholangitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All patients with an ICD-10 diagnosis of primary biliary cholangitis who had any records within the health system were included. A review of medical records was performed to confirm the diagnosis of primary biliary cholangitis and determine which medications had been prescribed for treatment, as well as candidacy for second-line therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 495 patients met inclusion criteria. Notably, 95% of patients were taking ursodeoxycholic acid for treatment of their primary biliary cholangitis, with 67% of patients having disease that was well-controlled on ursodeoxycholic acid monotherapy. In total, 8% of patients were taking obeticholic acid (either as combination or monotherapy). Only 3% would benefit from the addition of a second line therapy but had not yet been offered medication. Only 3% of patients were not on any medication for management of their primary biliary cholangitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ursodeoxycholic acid is a readily available and generally well-tolerated medication that should be offered to all patients with primary biliary cholangitis as first-line therapy. While prior investigations have suggested that up to 30% of patients with primary biliary cholangitis may never have received treatment for the disorder, the present study suggests that patients are generally being managed according to guidelines. Moreover, a significant proportion of patients with primary biliary cholangitis will qualify for second line therapies and prescribers should be aware of the indications to use these medications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-023-03108-4","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T09:02:06Z","timestamp":1704358926000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacotherapy for primary biliary cholangitis: an assessment of medication candidacy and rates of treatment"],"prefix":"10.1186","volume":"24","author":[{"given":"Nicholas","family":"MacDonald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Loh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Fenkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Sass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Halegoua-DeMarzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,4]]},"reference":[{"key":"3108_CR1","first-page":"1","volume":"0","author":"KD Lindor","year":"2018","unstructured":"Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2018 Practice Guidance from the American Association for the study of Liver Diseases. Hepatology. 2018;0:1\u201326.","journal-title":"Hepatology"},{"key":"3108_CR2","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S1089-3261(03)00101-6","volume":"4","author":"U Leuschner","year":"2003","unstructured":"Leuschner U. Primary biliary Cirrhosis\u2013presentation and diagnosis. Clin Liver Dis. 2003;4:741\u201358.","journal-title":"Clin Liver Dis"},{"key":"3108_CR3","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S0168-8278(05)80139-4","volume":"20","author":"TC Mahl","year":"1994","unstructured":"Mahl TC, Shockcor W, Boyer JL. Primary biliary Cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. J Hepatol. 1994;20:707\u201313.","journal-title":"J Hepatol"},{"key":"3108_CR4","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1053\/gast.2002.36027","volume":"123","author":"M Prince","year":"2002","unstructured":"Prince M, Chetwynd A, Newman W, Metcalf JV, James OF. Survival and symptom progression in a geographically based cohort of patients with primary biliary Cirrhosis: follow-up for up to 28 years. Gastroenterology. 2002;123:1044\u201351.","journal-title":"Gastroenterology"},{"key":"3108_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1572-0241.1999.00770.x","volume":"94","author":"J Springer","year":"1999","unstructured":"Springer J, Cauch-Dudek K, O\u2019Rourke K, Wanless IR, Heathcote EJ. Asymptomatic primary biliary Cirrhosis: a study of its natural history and prognosis. Am J Gastroenterol. 1999;94:47\u201353.","journal-title":"Am J Gastroenterol"},{"key":"3108_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM198301063080101","volume":"308","author":"J Roll","year":"1983","unstructured":"Roll J, Boyer JL, Barry D, Klatskin G. The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary Cirrhosis. N Engl J Med. 1983;308:1\u20137.","journal-title":"N Engl J Med"},{"key":"3108_CR7","first-page":"759","volume":"22","author":"B Combes","year":"1995","unstructured":"Combes B, Carithers RL Jr, Maddrey WC, Lin D, McDonald MF, Wheeler DE, et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary Cirrhosis. Hepatology. 1995;22:759\u201366.","journal-title":"Hepatology"},{"key":"3108_CR8","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1002\/hep.1840190512","volume":"19","author":"EJ Heathcote","year":"1994","unstructured":"Heathcote EJ, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, et al. The Canadian Multicenter Doubleblind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary Cirrhosis. Hepatology. 1994;19:1149\u201356.","journal-title":"Hepatology"},{"key":"3108_CR9","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1056\/NEJM199105303242204","volume":"324","author":"RE Poupon","year":"1991","unstructured":"Poupon RE, Balkau B, Eschwege E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary Cirrhosis. UDCA-PBC Study Group. N Engl J Med. 1991;324:1548\u201354.","journal-title":"N Engl J Med"},{"key":"3108_CR10","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","volume":"113","author":"RE Poupon","year":"1997","unstructured":"Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary Cirrhosis. Gastroenterology. 1997;113:884\u201390.","journal-title":"Gastroenterology"},{"key":"3108_CR11","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.cld.2018.03.007","volume":"22","author":"A Goel","year":"2018","unstructured":"Goel A, Kim WR. Natural history of primary biliary cholangitis in the Ursodeoxycholic Acid era: role of Scoring systems. Clin Liver Dis. 2018;22:563\u201378.","journal-title":"Clin Liver Dis"},{"key":"3108_CR12","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMoa1509840","volume":"375","author":"F Nevens","year":"2016","unstructured":"Nevens F, Andreone P, Mazzella G. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375:631\u201343.","journal-title":"N Engl J Med"},{"key":"3108_CR13","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1002\/hep.29569","volume":"67","author":"KV Kowdley","year":"2018","unstructured":"Kowdley KV, Luketic V, Chapman R, Hirschfield GM, Poupon R, Schramm C, et al. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. Hepatology. 2018;67:1890\u2013902.","journal-title":"Hepatology"},{"issue":"2","key":"3108_CR14","doi-asserted-by":"publisher","first-page":"232","DOI":"10.14309\/ajg.0000000000002070","volume":"118","author":"KV Kowdley","year":"2023","unstructured":"Kowdley KV, Bowlus CL, Levy C, Mayo MJ, Pratt DS, Vuppalanchi R, Younossi ZM. Application of the latest advances in evidence-based medicine in primary biliary cholangitis. Am J Gastroenterol. 2023;118(2):232\u201342.","journal-title":"Am J Gastroenterol"},{"key":"3108_CR15","unstructured":"US Food and Drug Administration. Due to risk of serious liver injury, FDA restricts use of Ocaliva (obeticholic acid) in primary biliary cholangitis (PBC) patients with advanced Cirrhosis. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/due-risk-serious-liver-injury-fda-restricts-use-ocaliva-obeticholic-acid-primary-biliary-cholangitis."},{"issue":"8","key":"3108_CR16","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.cgh.2017.10.018","volume":"16","author":"M Lu","year":"2018","unstructured":"Lu M, Li J, Haller IV, et al. Factors associated with prevalence and treatment of primary biliary cholangitis in United States health systems. Clin Gastroenterol Hepatol. 2018;16(8):1333\u20131341e6.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"3108_CR17","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.cgh.2017.12.033","volume":"16","author":"M Lu","year":"2018","unstructured":"Lu M, Zhou Y, Haller IV, et al. Increasing prevalence of primary biliary cholangitis and reduced mortality with treatment. Clin Gastroenterol Hepatol. 2018;16(8):1342\u20131350e1.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"3108_CR18","doi-asserted-by":"publisher","first-page":"262","DOI":"10.14309\/ajg.0000000000000512","volume":"115","author":"SC Gordon","year":"2020","unstructured":"Gordon SC, Wu KH, Lindor K, et al. Ursodeoxycholic acid treatment preferentially improves overall survival among African americans with primary biliary cholangitis. Am J Gastroenterol. 2020;115(2):262\u201370.","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"3108_CR19","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1097\/MEG.0000000000002033","volume":"33","author":"TW Warnes","year":"2021","unstructured":"Warnes TW, Roberts SA, Smith A, Cope VM, Vales P, Haboubi NY, McMahon RF. Portal Hypertension in primary biliary cholangitis: prevalence, natural history and histological correlates. Eur J Gastroenterol Hepatol. 2021;33(12):1595\u2013602.","journal-title":"Eur J Gastroenterol Hepatol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-03108-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-023-03108-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-03108-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T09:04:27Z","timestamp":1704359067000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-023-03108-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,4]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3108"],"URL":"https:\/\/doi.org\/10.1186\/s12876-023-03108-4","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,4]]},"assertion":[{"value":"24 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our study was reviewed by the Thomas Jefferson University Office of Human Research\u2019s institutional review board (IRB), and our study protocol was determined to be IRB exempt. The need for written informed consent was waived by the Thomas Jefferson University Office of Human Research\u2019s institutional review board (IRB).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Our study was reviewed by the Thomas Jefferson University Office of Human Research\u2019s institutional review board (IRB), and our study protocol was determined to be IRB exempt. This manuscript does not contain any individual person\u2019s data. All data are reported in aggregate form and consent for publication was therefore not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}